B-Cell Malignancies Market
Dec 15, 2023
BGB-16673 Breakthrough: A Tolerable Triumph in Rapid Clinical Responses for Relapsed/Refractory B-Cell Malignancies
Date of Abstract presentation11th December 2023IndicationsRelapsed or Refractory (R/R) B-Cell MalignanciesAbstract Number4401Abstract typePoster The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-1667...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
